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genetic factors with a defined genetic cause, and 
improved methodology for genotyping will enable 
rapid and (perhaps) inexpensive identification of 
individuals with deleterious (and protective) mark- 
ers. The real challenge will be to: 
* perform outcome studies to determine the 
relative importance of specific genes and 
alleles; 
• identify means to modulate the risks of spe- 
cific alleles; and 
• perform intervention trials to prove the 
clinical utility of both the tests and the 
interventions. 
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Mutations in the gene for fibrillin-1 have been 
implicated as etiologic in aneurysms associated with 
Marfan syndrome, but thc hereditary risk factors for 
more common aneurysmal conditions affecting the 
cerebral arteries and the aorta are uncertain. The 
present discussion will focus on the abdominal aor- 
tic aneurysm (AAA). 
The stereotype of the AAA patient is an aging 
white male smoker with a positive family history for 
the disease. A recent ultrasound screening study of 
the siblings ofAAA probands reaffirms this profile, 
with the three leading risk factors being male sex 
(12x increased risk), family history (4x increased 
risk), and age (2x increased risk). 1 Another large 
scale screening study of 73,451 American veterans 
had similar confirmatory data. The three leading 
"positive" risk factors for AAAs of 3.0 to 3.9 cm 
were smoldng, family history, and age (with odds 
ratios of 2.72, 1.96, and 1.52, respectively); and the 
three leading "negative" risk factors were female 
sex, diabetes, and black race (with odds ratios of 
0.62, 0.68, and 0.72, respectively). 2 It is possible 
that additional associations of AAA (for example, 
with inguinal hernia 3 nd with elongation of the 
internal carotid artery) 4 might also reflect heredi- 
tary risk factors. 
Several candidate genes have been considered and 
rejected by our group and others. Mutation in the 
gene for procollagen III cosegregated with AAA dis- 
ease in one family, 5 but further studies revealed that 
mutation of this gene is an infrequent cause of AAA 
in a larger population. 6 We reported apolymorphism 
of the gene for TIMP-1 in two of six AAA patients, 
but the transition was in the third position of the 
codon. The encoded amino acid was unchanged. The 
role, if any, for deficiency alleles of alpha-1 antitrypsin 
is unclear.7 
Considering that much recent evidence points to a 
role for autoimmunity in AAA degeneration, our 
group reported MHC Class II DR typing on a small 
group of North Americans (26) of mixed descent. 
Eighty-one percent of these individuals had a DR allele 
with phenylalanJne residues at positions 31 and 47 of 
the second hypervariable region; 35% had a double 
dose of a putative susceptibility allele. 7 HLA DR-15 is 
one of the alleles 7 with the above characteristics, and
HLA DR-15 has been implicated in a North American 
population of patients with inflammatory AAA. 8 In 
the more homogeneous population of Japan, DR-15 
was detected in 59% of 46 AAA patients versus 28% of 
50 control subjects. 9 Further study of this population 
suggested that HLA-DQ3 had a protective effect. 
If DR-15 positive and DQ-3 negative are the 
high-risk serotypes, then 89% of 36 AAA patients 
had one or both of these features, as compared with 
41% of 39 control subjects, l0 
Although genes among structural matrix pro- 
teins, proteinases, and proteinase inhibitors have 
been the leading candidates todate, the possible role 
of HLA DR and DQ genes merits more study. 
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The purpose of this presentation is to review the 
effects of transluminal ngioplasty on the biology of 
the arterial wall. The review will first focus on the 
acute effects of angioplasty on arterial wall structure 
and function and then focus on the biologic 
responses that take place in the dilated artery. 
Acute effects of balloon angioplasty on the arte- 
rial wall 
The principle objective of balloon angioplasty is
to increase the luminal diameter of the stenotic 
artery whose diameter was reduced by the presence 
of an atherosclerotic lesion. The mechanism(s) by 
which balloon angioplasty increase lumen diameter 
include (in order of magnitude) 
• circumferential stretching of arterial wall producing 
longitudinal tears of the plaque and internal elastic 
lamina and irreversibly stretching the collagen 
fibers of arterial wall 
• redistribution of plaque longitudinally 
• plaque compression and extrusion of fluid 
• embolization of plaque 
The acute effects of balloon angioplasty on the 
arterial wall are summarized below. 
Endothelial denudation. Injury/destruction f 
the endothelium results in a reduction/elimination 
of the endothelium-derived factors that normally 
inhibit platelet adhesion/aggregation and thrombus 
formation (prostacyclin, nitric oxide, plasminogen 
activators), inhibit recruitment of leukocytes (nitric 
oxide, low selectin and chemoattractant produc- 
tion), inhibit vascular smooth muscle contraction 
(nitric oxide, prostacyclin), and inhibit smooth mus- 
cle migration and proliferation (prostacyclin, itric 
oxide, heparan sulfate). 
Plaque disruption. Tearing of plaque exposes 
underlying thrombogenic surfaces resulting in platelet 
adhesion, aggregation, and degranulation, which 
releases factors including platelet-derived growth fac- 
tor, a potent smooth muscle cell chemoattractant, and 
mitogen. Plaque disruption also releases tissue factor 
that activates the extrinsic coagulation pathway lead- 
hag to the formation of thrombin that promotes both 
fibrin formation and smooth muscle proliferation. 
Medial injury. Balloon dilation of the artery 
injures and lyses vascular smooth muscle cells and 
irreversibly stretches elastin and collagen. Depending 
on the magnitude of the injury, arterial contractility 
can increase (vasospasm) in response to the release of 
serotonin from platelets and/or endothelin from 
injured endothelial cells. Alternatively, contractility 
can decrease, even to the point of paralysis. Medial 
injury can increase fluid conductivity and decrease 
wall thickness, factors that affect arterial permeability 
to growth factors and cytokines.1 
Technical factors. A number of technical variables 
influence the effects of angioplasty on the arterial wall. 
For example, an increase in the balloon-artery atio 
increases arterial stretch, which decreases the likeli- 
hood of elastic recoil but also increases the likelihood 
of arterial injury and cell death. Increasing the dura- 
tion of balloon inflation, while not causing further 
changes in passive arterial mechanics, can increase 
vascular smooth muscle cell injury and decrease 
contractility. 
Responses to angioplasty-induced arterial injury 
Platelet deposition. Radiolabeled platelet stud- 
ies have demonstrated that platelet recruitment 
begins immediately after angioplasty, peaks in about 
an hour, and subsides over the next several days. The 
magnitude of recruitment appears to be directly 
related to the severity of the injury. 2 
Inflammation. After balloon angioplasty, poly- 
morphonuclear leukocytes and monocytes are 
attracted to the injured arterial wall. Neutrophil 
accumulation begins within an hour after angioplas- 
ty and continues for days to weeks. Monocyte accu- 
mulation begins within a day and peaks 1 to 2 weeks 
after angioplasty. 3 At least four mechanisms are 
potentially involved in the recruitment ofleukocytes 
to the site of arterial injury. These include activation 
